Drugs Containing Excipient (Inactive Ingredient) ETHYL LACTATE

Branded drugs containing ETHYL LACTATE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Agile Therapeutics Inc	TWIRLA	levonorgestrel/ethinyl estradiol	71671-100	ETHYL LACTATE

Generic drugs containing ETHYL LACTATE excipient

Company	Ingredient	NDC	Excipient
Agile Therapeutics Inc	levonorgestrel/ethinyl estradiol	71671-100	ETHYL LACTATE

Ethyl Lactate Pharmaceutical Excipient Market Dynamics and Financial Trajectory

Last updated: August 27, 2026

Ethyl lactate is a bio-based ester solvent used in pharmaceutical processing, topical formulations, coatings, cleaning systems, and selected drug-delivery applications. Its commercial position is strongest where manufacturers need a biodegradable, low-toxicity solvent with favorable regulatory and sustainability characteristics. The pharmaceutical-excipient segment is small relative to industrial and electronics demand, and no major supplier publicly reports ethyl lactate revenue as a standalone product.

The financial outlook is positive but exposed to feedstock prices, purity requirements, regional chemical regulation, and substitution by ethanol, ethyl acetate, propylene carbonate, acetone, and other solvents. The molecule itself has no meaningful composition-of-matter exclusivity. Commercial differentiation depends on pharmaceutical grade, impurity control, documentation, supply reliability, and process qualification.

What is ethyl lactate and how is it used in pharmaceuticals?

Ethyl lactate is the ethyl ester of lactic acid, with CAS Registry Number 97-64-3 and molecular formula C5H10O3. It is a colorless, polar organic solvent that can dissolve selected resins, polymers, active ingredients, and excipients.

Pharmaceutical uses include:

• Solvent or co-solvent in topical, transdermal, and semisolid formulations.
• Processing solvent for coatings, granulation, crystallization, and cleaning.
• Solvent in drug-delivery research involving polymeric films and nanoparticles.
• Component in pharmaceutical manufacturing systems seeking lower volatile-organic-compound toxicity.
• Potential replacement for chlorinated solvents and certain high-toxicity glycol ethers.

Ethyl lactate is not usually the therapeutic component of a drug. Its economic value comes from manufacturing performance, formulation compatibility, and compliance with pharmaceutical quality systems.

The compound is produced primarily by esterification of lactic acid with ethanol or through integrated fermentation and esterification routes. Bio-based production uses carbohydrate feedstocks such as corn, sugar, or other fermentable biomass. Petroleum-derived and mixed-feedstock supply chains also exist.

How large is the ethyl lactate market?

The total ethyl lactate market includes pharmaceutical, electronics, paints and coatings, adhesives, industrial cleaning, food, and cosmetics applications. Public market studies generally place the global market in the high hundreds of millions of U.S. dollars, but estimates vary because analysts use different definitions of product scope, geographic coverage, and downstream applications.

The pharmaceutical-excipient portion is materially smaller than the total market. Public company filings do not identify pharmaceutical ethyl lactate revenue separately. A practical market structure is:

Segment	Commercial role	Relative demand
Paints and coatings	Solvent for resins and coatings	Largest or near-largest
Electronics	Cleaning and processing solvent	High-value, specification-sensitive
Industrial cleaning	Biodegradable solvent	Established
Pharmaceuticals	Excipient and process solvent	Smaller, higher compliance value
Cosmetics and personal care	Solvent and formulation aid	Moderate
Food and flavor	Flavoring and processing applications	Smaller

Third-party market forecasts commonly project mid-single-digit to high-single-digit annual growth through the end of the decade. The pharmaceutical segment can grow faster than the total market if solvent substitution, continuous manufacturing, and sustainable chemistry programs expand. That growth does not automatically translate into high margins because bulk ethyl lactate remains a competitive commodity.

What drives ethyl lactate pharmaceutical demand?

Demand is driven by four commercial factors.

Solvent substitution

Pharmaceutical manufacturers are reducing or reviewing solvents classified as hazardous, persistent, or difficult to manage under environmental, health, and safety programs. Ethyl lactate has a favorable toxicological and environmental profile relative to several conventional solvents, although its suitability depends on the application and exposure scenario.

The International Council for Harmonisation solvent framework evaluates residual solvents by risk class. Ethyl lactate is generally treated as a lower-concern solvent than many class 2 solvents, but formulation and manufacturing decisions still require process-specific control and residual-solvent testing. ICH Q3C does not eliminate the need for specification setting or validation. (International Council for Harmonisation, 2021)

Sustainable chemistry programs

Bio-based content is a central selling point. Suppliers can offer ethyl lactate made from fermented lactic acid, giving pharmaceutical companies a renewable-feedstock narrative for solvent selection and environmental reporting.

The sustainability premium is strongest in regulated manufacturing, specialty coatings, and electronics. It is weaker in price-sensitive bulk pharmaceutical operations where solvent cost, recovery, and process yield dominate.

Growth in topical and advanced delivery systems

Ethyl lactate can support solvent systems for films, patches, coatings, and semisolid products. Its polarity and evaporation characteristics make it relevant to formulation development, although compatibility with polymers, permeation enhancers, APIs, and packaging must be established experimentally.

Supplier qualification and dual sourcing

Pharmaceutical buyers value suppliers that provide:

• GMP or pharmaceutical-quality manufacturing controls.
• Lot traceability.
• Residual-solvent and elemental-impurity data.
• Water, acidity, ester, and assay specifications.
• Change-control notification.
• Stability and packaging data.
• Regional regulatory support.

These requirements create switching costs that are higher than in industrial solvent markets.

What is the financial trajectory for pharmaceutical-grade ethyl lactate?

The financial trajectory is a gradual expansion of volume with selective margin premiums for qualified grades.

Financial factor	Direction through 2030	Effect on suppliers
Pharmaceutical demand	Moderate growth	Positive volume
Bio-based solvent demand	Moderate to strong growth	Supports premium pricing
Lactic acid feedstock cost	Volatile	Pressures gross margin
Ethanol cost	Regionally variable	Affects conversion economics
Pharmaceutical qualification	Slow but sticky	Improves customer retention
Industrial competition	Persistent	Limits commodity pricing
Recovery and recycling	Increasing	Reduces new-solvent consumption
Regional supply concentration	Material	Creates logistics and inventory risk

Revenue growth is likely to come from a mix of market expansion and higher-specification products rather than from major price increases. Suppliers with pharmaceutical documentation, low color, controlled water content, consistent odor, and narrow impurity profiles can earn a premium over technical-grade material.

Public financial disclosures do not provide a reliable standalone revenue figure for pharmaceutical-grade ethyl lactate. Most suppliers report broader solvent, lactate, specialty chemical, or performance-materials segments. As a result, company-level exposure must be assessed through production assets, product catalogs, regional distribution, and customer qualification rather than reported ethyl lactate revenue.

Which companies supply ethyl lactate?

The competitive field includes bio-based lactate producers, specialty solvent manufacturers, and chemical distributors.

Companies publicly associated with ethyl lactate or related lactate-solvent portfolios include:

• Corbion, through its lactic-acid and lactate derivatives platform.
• Galactic, which markets bio-based lactic-acid derivatives and solvents.
• Vertec BioSolvents, a specialty supplier of bio-based solvents.
• Regional Asian producers supplying industrial and specialty grades.
• Specialty distributors such as Merck and TCI for laboratory and formulation-development quantities.

The supplier landscape differs by region. China and other Asian manufacturing centers provide substantial bulk capacity. European and North American suppliers often compete through renewable feedstock, regulatory documentation, local inventory, and technical support.

No single supplier has a legally protected pharmaceutical monopoly. The most defensible commercial positions are based on qualified manufacturing sites, customer-specific specifications, validated processes, and reliable supply.

What regulatory status does ethyl lactate have in the pharmaceutical industry?

Ethyl lactate is an excipient or process solvent, not an approved active pharmaceutical ingredient. Its regulatory treatment depends on the intended use, route of administration, quantity, residual level, and finished-product formulation.

Relevant regulatory considerations include:

• FDA inactive-ingredient acceptability for specific routes and dosage forms.
• Current USP-NF, FCC, or other applicable compendial specifications.
• ICH Q3C residual-solvent expectations.
• European Union excipient quality and risk-assessment requirements.
• GMP controls under pharmaceutical manufacturing regulations.
• Extractables, leachables, and packaging compatibility.
• Toxicological justification for novel routes or unusually high exposure.

The FDA Inactive Ingredient Database is route- and dosage-form-specific. An entry does not constitute universal approval for all products or concentrations. Sponsors must assess whether the proposed use falls within established precedent and must justify new or materially different use cases. (U.S. Food and Drug Administration, n.d.)

What is the Orange Book status of ethyl lactate?

Ethyl lactate has no standalone Orange Book status because it is not an approved drug product. It has no Orange Book-listed active-ingredient patent estate, no independent New Drug Application exclusivity, and no standalone Paragraph IV pathway.

Orange Book issues arise only when ethyl lactate is used in a finished drug product. A sponsor may list patents covering the drug product, formulation, delivery system, or method of use, but those patents protect the finished medicine rather than ethyl lactate as a chemical excipient. (U.S. Food and Drug Administration, 2024)

What patents protect ethyl lactate?

The core ethyl lactate molecule is old and outside modern composition-of-matter patent protection. Patent risk is therefore concentrated in applications and manufacturing processes.

Potential patent categories include:

Patent category	Risk level for ethyl lactate suppliers
Composition of matter	Negligible
Esterification process	Low to moderate
Fermentation and bio-based production	Moderate
Purification and impurity control	Moderate
Pharmaceutical formulation	Application-specific
Drug-delivery system	Application-specific
Packaging and solvent recovery	Low to moderate

A company could patent a process for producing low-water, low-acid, low-aldehyde ethyl lactate, but such claims must overcome prior art covering esterification, distillation, reactive separation, fermentation, and solvent purification.

Method-of-use patents may cover ethyl lactate in a particular topical system, coating, transdermal device, or manufacturing process. Those rights would not prevent other suppliers from selling the molecule for unrelated uses.

Are there Paragraph IV challenges or litigation involving ethyl lactate?

There is no meaningful Paragraph IV litigation directed at ethyl lactate as an excipient. Paragraph IV certifications apply to abbreviated new drug applications challenging patents listed for reference-listed drug products. Ethyl lactate itself is not a reference-listed drug.

Publicly visible litigation risk is more likely to involve:

• Finished dosage-form patents.
• Transdermal or topical delivery systems.
• Solvent-selection patents.
• Manufacturing-process claims.
• Trade secrets involving purification or formulation.
• Contract disputes over pharmaceutical-grade specifications.

No broad settlement landscape is associated with ethyl lactate as a standalone pharmaceutical ingredient. Any settlement would typically concern a finished drug product or a supplier agreement rather than the molecule.

How strong is the ethyl lactate patent estate?

The standalone patent estate is weak. The commercial moat is operational rather than molecular.

Strength assessment:

Dimension	Assessment
Core molecule exclusivity	Very weak
Regulatory exclusivity	None as a standalone excipient
Manufacturing know-how	Moderate
Pharmaceutical qualification	Moderate
Customer switching barriers	Moderate
Supplier differentiation	Moderate
Formulation-specific protection	Variable
Generic substitution risk	High for unprotected solvent use

The strongest defensible assets are validated production processes, impurity specifications, customer approvals, supply contracts, and integrated lactic-acid feedstock access.

What generic entry and substitution risks exist?

Generic substitution risk is high because multiple producers can manufacture ethyl lactate and because the molecule is chemically well established. A drug manufacturer can often qualify an alternative supplier if the substitute meets the same specification and performs equivalently.

The main barriers are:

• Revalidation of the manufacturing process.
• Stability and compatibility studies.
• Regulatory filing updates.
• Supplier audits.
• Change-control review.
• Batch-to-batch performance.
• Regional transport and hazardous-material requirements.

Substitution by other solvents is also possible. Ethanol, ethyl acetate, acetone, methyl ethyl ketone, propylene glycol, and propylene carbonate can compete depending on solubility, evaporation rate, toxicity profile, water sensitivity, and formulation requirements.

Ethyl lactate is most defensible where the solvent is embedded in a validated process and where environmental or toxicological objectives favor it over conventional alternatives.

What manufacturing and intellectual-property barriers affect supply?

The key manufacturing risks are feedstock cost, esterification conversion, water removal, acid control, and purification. Pharmaceutical-grade material requires tighter control than industrial-grade solvent, particularly for:

• Assay.
• Water.
• Free lactic acid.
• Ethanol.
• Ethyl acetate and other volatile impurities.
• Aldehydes.
• Color.
• Nonvolatile residue.
• Microbial and packaging contamination, where relevant to the use.

Integrated producers that control lactic acid and ethanol inputs have an economic advantage during feedstock volatility. Regional producers with lower conversion costs can pressure prices, while Western suppliers may command premiums for documentation and local inventory.

Intellectual-property barriers are strongest in proprietary fermentation organisms, purification sequences, solvent-recovery systems, and customer-specific formulations. They are not strong at the molecule level.

How does ethyl lactate compare with other pharmaceutical solvents?

Solvent	Relative advantage	Main limitation
Ethyl lactate	Renewable potential, favorable solvent profile, useful polarity	Hydrolysis sensitivity and variable drying behavior
Ethanol	Familiar regulatory history and broad use	Flammability and limited solvency for some materials
Ethyl acetate	Low cost and fast evaporation	More volatile and less polar
Acetone	Strong solvency and rapid evaporation	High volatility and flammability
Propylene glycol	Low volatility and established formulation use	May be unsuitable where rapid evaporation is needed
Propylene carbonate	Strong polarity and low volatility	Higher cost and narrower formulation familiarity

Ethyl lactate occupies a middle position: more sustainable and less volatile than some alternatives, but less universally familiar than ethanol or acetone.

What is the outlook for ethyl lactate through 2030?

The base case is moderate growth, with the pharmaceutical segment expanding faster than commodity industrial demand but remaining a niche portion of total consumption.

Upside drivers include:

• Greater adoption of renewable solvents.
• Growth in topical, transdermal, and polymer-based delivery.
• Pharmaceutical companies’ solvent-reduction programs.
• Expansion of regional pharmaceutical manufacturing.
• Greater use of bio-based raw materials in supplier qualification.

Downside risks include:

• Low-cost Asian capacity.
• Substitution by ethanol or ethyl acetate.
• Solvent recovery reducing new purchases.
• Feedstock inflation.
• Limited willingness to pay for renewable content.
• Slow regulatory acceptance for new dosage-form applications.

Revenue growth will favor suppliers that sell qualified pharmaceutical material, formulation support, and supply assurance. Commodity-grade producers will remain exposed to price competition and cyclical industrial demand.

Key Takeaways

• Ethyl lactate is a bio-based solvent and pharmaceutical excipient with growing relevance in sustainable manufacturing.
• Pharmaceutical demand is smaller than coatings, electronics, and industrial-cleaning demand.
• No standalone Orange Book exclusivity, Paragraph IV dispute, or meaningful composition patent protects the molecule.
• The strongest commercial barriers are pharmaceutical qualification, impurity control, process validation, and supply reliability.
• Public companies do not separately disclose pharmaceutical ethyl lactate revenue.
• Financial growth should be moderate, with better margins for GMP-controlled and specification-intensive grades.
• Generic and supplier-substitution risk is high unless ethyl lactate is embedded in a validated formulation or manufacturing process.
• The principal competitive threat is substitution by ethanol, ethyl acetate, acetone, and other established solvents.

FAQs

Is ethyl lactate listed as an inactive ingredient by the FDA?

FDA inactive-ingredient status must be evaluated by route of administration, dosage form, and listed concentration. An entry for one use does not establish universal approval for all pharmaceutical applications.

Can ethyl lactate be used in injectable drugs?

Injectable use requires route-specific safety, purity, residual-solvent, compatibility, and toxicological evaluation. Common use in industrial or topical applications does not establish suitability for parenteral products.

Does ethyl lactate qualify as a green pharmaceutical solvent?

Ethyl lactate is often classified as a preferred or greener solvent because it can be produced from renewable lactic acid and has a comparatively favorable environmental profile. A project-specific assessment must still consider production energy, feedstock, recovery, waste, and worker exposure.

Can a pharmaceutical company switch ethyl lactate suppliers without a new clinical trial?

A supplier change may be possible without new clinical trials when the material remains within approved specifications and the change has no effect on product quality. The sponsor must assess regulatory filing requirements, process validation, stability, and comparability.

Is ethyl lactate a high-margin specialty chemical?

Pharmaceutical-grade ethyl lactate can earn a premium over technical-grade material, but the molecule remains broadly available. Margin depends on quality systems, qualification status, supply contracts, feedstock integration, and customer-specific specifications rather than chemical exclusivity.

References

International Council for Harmonisation. (2021). Q3C(R8): Impurities: Guideline for residual solvents. https://www.ich.org

U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=inactiveIngredient

U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

U.S. Environmental Protection Agency. (2023). Safer Choice program and solvent selection resources. https://www.epa.gov/saferchoice

European Chemicals Agency. (n.d.). Ethyl lactate substance information. https://echa.europa.eu**